As of 2024-12-15, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is -0.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is 14.43 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2024-12-13 | -0.34 |
| 2024-12-12 | -0.33 |
| 2024-12-11 | -0.34 |
| 2024-12-10 | -0.37 |
| 2024-12-09 | -0.38 |
| 2024-12-06 | -0.40 |
| 2024-12-05 | -0.35 |
| 2024-12-04 | -0.39 |
| 2024-12-03 | -0.38 |
| 2024-12-02 | -0.40 |
| 2024-11-29 | -0.41 |
| 2024-11-27 | -0.39 |
| 2024-11-26 | -0.37 |
| 2024-11-25 | -0.42 |
| 2024-11-22 | -0.40 |
| 2024-11-21 | -0.38 |
| 2024-11-20 | -0.37 |
| 2024-11-19 | -0.37 |
| 2024-11-18 | -0.38 |
| 2024-11-15 | -0.39 |
| 2024-11-14 | -0.40 |
| 2024-11-13 | -0.42 |
| 2024-11-12 | -0.44 |
| 2024-11-11 | -0.47 |
| 2024-11-08 | -0.50 |
| 2024-11-07 | -0.41 |
| 2024-11-06 | -0.43 |
| 2024-11-05 | -0.39 |
| 2024-11-04 | -0.40 |
| 2024-11-01 | -0.43 |
| 2024-10-31 | -0.43 |
| 2024-10-30 | -0.41 |
| 2024-10-29 | -0.45 |
| 2024-10-28 | -0.45 |
| 2024-10-25 | -0.41 |
| 2024-10-24 | -0.38 |
| 2024-10-23 | -0.32 |
| 2024-10-22 | -0.27 |
| 2024-10-21 | -0.24 |
| 2024-10-18 | -0.23 |
| 2024-10-17 | -0.22 |
| 2024-10-16 | -0.24 |
| 2024-10-15 | -0.23 |
| 2024-10-14 | -0.23 |
| 2024-10-11 | -0.24 |
| 2024-10-10 | -0.24 |
| 2024-10-09 | -0.24 |
| 2024-10-08 | -0.24 |
| 2024-10-07 | -0.25 |
| 2024-10-04 | -0.25 |